Drug Trial Radar · NCT05751642
Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Nov 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Apr 19, 2023
Primary completion
Dec 4, 2023
Study completion Dec 4, 2023
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Mar 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single ascending doses (SADs) of ALXN1920 subcutaneous (SC) and of a single dose of ALXN1920 intravenous (IV) in healthy adult participants.
Conditions
- Healthy Participants
Interventions
ALXN1920Biological
Participants will receive a single dose of ALXN1920 by Subcutaneous (SC) injection.
PlaceboBiological
Participants will receive a single dose of Placebo by SC injection, SC infusion or IV infusion.
ALXN1920Biological
Participants will receive a single dose of ALXN1920 by SC infusion.
ALXN1920Biological
Participants will receive a single dose of ALXN1920 by Intravenous (IV) infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse events (AEs)Time frame: Up to End of study visit (Day 29)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Christchurch, New Zealand
Clinical Trial Site
Grafton, Auckland, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.